-
EP4146648
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4146648
| EP4146648 - IAP ANTAGONIST COMPOUNDS AND INTERMEDIATES AND METHODS FOR SYNTHESIZING THE SAME [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 22.08.2024 Database last updated on 30.10.2024 | |
| Former | Request for examination was made Status updated on 10.02.2023 | ||
| Former | The international publication has been made Status updated on 12.11.2021 | ||
| Former | unknown Status updated on 09.06.2021 | Most recent event Tooltip | 24.08.2024 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states Otsuka Pharmaceutical Co., Ltd. 2-9, Kanda Tsukasa-machi Chiyoda-ku Tokyo 101-8535 / JP | [2023/11] | Inventor(s) | 01 /
BODHURI, Prabhudas Pleasanton, California 94588 / US | 02 /
KHATRI, Hem Raj Pleasanton, California 94588 / US | 03 /
DAVAR, Nipun Pleasanton, California 94588 / US | 04 /
SCOTT, Ian Pleasanton, California 94588 / US | [2023/11] | Representative(s) | Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW / GB | [2023/11] | Application number, filing date | 21728682.2 | 03.05.2021 | [2023/11] | WO2021US30456 | Priority number, date | US202063019865P | 04.05.2020 Original published format: US 202063019865 P | US202063019874P | 04.05.2020 Original published format: US 202063019874 P | [2023/11] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021225955 | Date: | 11.11.2021 | Language: | EN | [2021/45] | Type: | A1 Application with search report | No.: | EP4146648 | Date: | 15.03.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 11.11.2021 takes the place of the publication of the European patent application. | [2023/11] | Search report(s) | International search report - published on: | EP | 11.11.2021 | Classification | IPC: | C07D471/04, C07D241/04, C07D413/06 | [2023/11] | CPC: |
C07D471/04 (EP,KR,US);
C07D213/61 (US);
C07D241/04 (EP,KR,US);
C07D413/04 (KR);
C07D413/06 (EP,KR,US);
C07F5/025 (EP,KR);
C07F5/04 (US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/11] | Title | German: | IAP-ANTAGONISTEN-VERBINDUNGEN UND ZWISCHENPRODUKTE UND VERFAHREN ZU IHRER SYNTHESE | [2023/11] | English: | IAP ANTAGONIST COMPOUNDS AND INTERMEDIATES AND METHODS FOR SYNTHESIZING THE SAME | [2023/11] | French: | COMPOSÉS ANTAGONISTES D'IAP ET INTERMÉDIAIRES ET LEURS PROCÉDÉS DE SYNTHÈSE | [2023/11] | Entry into regional phase | 02.12.2022 | National basic fee paid | 02.12.2022 | Designation fee(s) paid | 02.12.2022 | Examination fee paid | Examination procedure | 02.12.2022 | Examination requested [2023/11] | 02.12.2022 | Date on which the examining division has become responsible | 30.06.2023 | Amendment by applicant (claims and/or description) | 23.08.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 14.03.2023 | Renewal fee patent year 03 | 13.03.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]US2010256097 (ALTMAN MICHAEL [US], et al); | [A]WO2014089324 (CALITOR SCIENCES LLC [US], et al); | [XA]WO2015092420 (ASTEX THERAPEUTICS LTD [GB]); | by applicant | US9018214 | US9617248 | US9617283 | US9663512 | US9676768 | US9783538 | US9980973 |